NVTA - Invitae Corporation

NYSE - NYSE Delayed Price. Currency in USD
12.04
-0.43 (-3.45%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close12.47
Open12.35
Bid11.82 x 800
Ask12.70 x 800
Day's Range11.88 - 12.65
52 Week Range4.35 - 18.38
Volume644,170
Avg. Volume1,129,668
Market Cap898.391M
Beta (3Y Monthly)2.46
PE Ratio (TTM)N/A
EPS (TTM)-2.30
Earnings DateFeb 12, 2018 - Feb 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.55
Trade prices are not sourced from all markets
  • Do Hedge Funds Love InVitae Corporation (NVTA)?
    Insider Monkey17 hours ago

    Do Hedge Funds Love InVitae Corporation (NVTA)?

    Is InVitae Corporation (NYSE:NVTA) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]

  • TheStreet.com4 days ago

    Here Are 3 Small-Cap Names for Biotech Investors to Consider

    Today, we look at a slightly riskier part of the sector in promising small caps that should be able to reach profitability with little to no additional funding needs. Revenues should more than double this year to over $140 million as the genetic test market continues to expand rapidly and Invitae garners market share. The company is doing a good job lessening its cash burn every quarter and is on the path to reach profitability late in 2019.

  • MoneyShow10 days ago

    Invitae- The Second Time Around

    In 2017, Invitae Corporation (NVTA) was growing at a rapid clip. But it was burning through cash at an even faster one. So, we advised everyone to sell it for a 50% gain, recalls Brit Ryle, growth stock specialist and editor of The Wealth Advisory.

  • New Study Published in Journal of Clinical Oncology Supports Universal Genetic Testing for all Breast Cancer Patients
    PR Newswire6 days ago

    New Study Published in Journal of Clinical Oncology Supports Universal Genetic Testing for all Breast Cancer Patients

    SAN FRANCISCO, Dec. 10, 2018 /PRNewswire/ -- Current guidelines for genetic testing of breast cancer patients miss as many patients with pathogenic variants (or genetic mutations) as they find, according to a new study published in the Journal of Clinical Oncology by researchers from the TME Breast Care Network, a network of more than 300 leading breast cancer physicians and Invitae (NVTA), one of the fastest growing genetics companies. The findings support broadening and simplifying current guidelines to ensure all breast cancer patients have access to genetic information to guide their breast cancer care, potential screening for other cancers, and inform their family's health.

  • GlobeNewswire12 days ago

    Detailed Research: Economic Perspectives on United Technologies, Walmart, Invitae, Emergent Biosolutions, U.S. Physical Therapy, and Amdocs — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • This High-Growth Biotech Industry Is as Competitive as Ever Heading Into 2019
    Motley Fool29 days ago

    This High-Growth Biotech Industry Is as Competitive as Ever Heading Into 2019

    Three short years ago, Myriad Genetics was the undisputed leader of the genetic testing industry. A persistent competitor just challenged the diagnostic company -- and a second one is nipping at its heels.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of NVTA earnings conference call or presentation 7-Nov-18 9:30pm GMT

    Q3 2018 Invitae Corp Earnings Call

  • Invitae Highlighting New Research, Honoring Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 37th Annual Conference
    PR Newswirelast month

    Invitae Highlighting New Research, Honoring Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 37th Annual Conference

    ATLANTA, Nov. 14, 2018 /PRNewswire/ -- Researchers from Invitae Corporation (NVTA), one of the fastest growing genetics companies, are presenting research at the National Society of Genetic Counselors (NSGC) 37th Annual Conference in Atlanta that further underscores the frequency of medically actionable genetic variants and their utility in clinical care. In addition to its research presentations, the company is supporting the Code Talker award, which recognizes excellence in the field of genetic counseling. Currently, the American College of Medical Genetics and Genomics (ACMG) recommends reporting clinically significant genetic variants in 59 genes as secondary findings for individuals who undergo whole exome or whole genome sequencing, regardless of the original indication for testing.

  • GuruFocus.comlast month

    It May Be Time to Buy Invitae

    Invitae Corp. (NVTA) is a genetic testing company based in San Francisco, whose stated aim is to aggregate the large number of different genetic tests currently available to patients into one single service. It is currently trading around $12.50 per share and has a market capitalization of $970 million. The company's value proposition is to decrease the costs of obtaining and using genetic information for both doctors and patients.

  • Why Invitae Corporation Is Tanking Today
    Motley Foollast month

    Why Invitae Corporation Is Tanking Today

    Shares cool off after an amazing year-to-date run, even though the genetic testing specialist reported upbeat third-quarter results.

  • Here's Why Invitae Lost 15.2% in October
    Motley Foollast month

    Here's Why Invitae Lost 15.2% in October

    The fast-growing leader in genetic testing soared past a $1 billion market cap in September. Investors reconsidered prior to the release of third-quarter 2018 earnings.

  • Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates
    Zackslast month

    Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates

    Invitae (NVTA) delivered earnings and revenue surprises of 4.26% and 8.59%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Invitae: 3Q Earnings Snapshot

    The San Francisco-based company said it had a loss of 45 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...

  • Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume in Third Quarter 2018
    PR Newswirelast month

    Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume in Third Quarter 2018

    -- Raising annual volume and revenue guidance amid strong performance -- -- Q3 2018 gross profit of $16.9M up from nearly $5.0M in Q3 2017 -- -- Management hosting conference call and webcast today at ...

  • Invitae (NVTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks2 months ago

    Invitae (NVTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria
    PR Newswire2 months ago

    Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria

    SAN FRANCISCO, Oct. 29, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, announced today it has expanded its partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to provide genetic testing at no cost to patients through the Alnylam Act® program for individuals who may carry gene mutations associated with primary hyperoxaluria, an ultra-rare genetic disorder affecting the kidneys that most often presents in childhood. The Alnylam Act® program was developed to reduce barriers to genetic testing and counseling in order to help people make informed decisions about their health.

  • Invitae to announce third quarter 2018 financial results on November 7, 2018
    PR Newswire2 months ago

    Invitae to announce third quarter 2018 financial results on November 7, 2018

    SAN FRANCISCO , Oct. 24, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its third quarter 2018 financial results ...

  • Research shows high positive rate for risk of hereditary disease in study of proactive genetic health screening for healthy people
    PR Newswire2 months ago

    Research shows high positive rate for risk of hereditary disease in study of proactive genetic health screening for healthy people

    SAN DIEGO, Oct. 17, 2018 /PRNewswire/ -- Researchers from Invitae Corporation (NVTA), one of the fastest growing genetics companies, will present findings showing proactive genetic testing identifies medically significant findings for 16.5 percent of healthy individuals. The data add to a growing body of evidence showing expanding clinical genetic testing to people without identified risks could be beneficial. The platform presentation is among the company's data being presented this week at The American Society of Human Genetics (ASHG) annual meeting in San Diego.

  • Here's Why Invitae Jumped 13% in September
    Motley Fool2 months ago

    Here's Why Invitae Jumped 13% in September

    The double-digit move follows a 67.5% leap in August, but was followed by a 19% drop in the first 10 days of October.

  • Is Invitae Corporation (NYSE:NVTA) Still A Cheap Healthcare Stock?
    Simply Wall St.3 months ago

    Is Invitae Corporation (NYSE:NVTA) Still A Cheap Healthcare Stock?

    Invitae Corporation (NYSE:NVTA), a US$1.26b small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging population andRead More...

  • Invitae to Present at the Ladenburg Thalmann 2018 Healthcare Conference
    PR Newswire3 months ago

    Invitae to Present at the Ladenburg Thalmann 2018 Healthcare Conference

    SAN FRANCISCO, Sept. 18, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:00 a.m. Eastern / 6:00 a.m. Pacific in New York City. Invitae Corporation (NVTA) is a genetics company whose mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people.

  • PR Newswire3 months ago

    Invitae Appoints Chitra Nayak to its Board of Directors

    SAN FRANCISCO, Sept. 11, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, announced the appointment of Chitra Nayak to its Board of Directors, effective September 10, 2018. "We are pleased to welcome Chitra Nayak to our board of directors and look forward to working with her, taking full advantage of her considerable track record of helping companies achieve transformational growth to scale and innovate globally," said Sean George, co-founder and chief executive officer of Invitae. "Chitra has deep operational and commercial leadership expertise in growing market share and strengthening industry leadership positions for rapidly growing companies, including organizations like ours that are transforming highly competitive industries.

  • Implied Volatility Surging for Invitae (NVTA) Stock Options
    Zacks3 months ago

    Implied Volatility Surging for Invitae (NVTA) Stock Options

    Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.